JUBLINGREA said that its estimated cash outflow of FY23 will be around INR550 crore and for FY24 and FY25 will be INR650 crore and INR600 crore respectively, which are intended to be funded through internal accrual along with reduction in debt.
Q&A Insights: Rahul Veera of @AbakkusInvest asked about the breakup of INR1,250 crore incremental investment. Shyam Bhartia Chairman replied that specialty chemical is INR750 crore, nutrition and health solution is INR200 crore, and chemical intermediates is INR300 crores.
Q&A Insights: Siddharth Gadekar with @EquirusGroup asked about the reason for sharp jump in other expenses during 4Q22. Shyam Bhartia Chairman said that there was one re-class in other expenses. Other than that, the increase was due to higher freight expenses and some writeoffs.
Q&A Insights: Siddharth Gadekar with @EquirusGroup also enquired that given acetic acid prices are down vs. 4Q22 avg., if the company would see more inventory loss in 1Q23. Shyam Bhartia Chairman replied that there has not been major changes in acetic acid prices.
Q&A Insights: Rohan Gupta of @EdelweissFin asked about the optimism in capex of another INR1,200 crore. Shyam Chairman said that it is driven by customer demand; existing customers asking to develop new products, value addition in existing product and investment in new platforms.
Q&A Insights: Rohan Gupta of @EdelweissFin asked how much investment has gone in cash outflow in FY22. Shyam Chairman said that FY22 cash outflow is close to INR243 crore. And since most of the capex have been approved during FY22, cash outflow will mainly start happening in FY23
Q&A Insights: Rohan Gupta of @EdelweissFin asked that going forward the percentage margins, which was upwards of 20% can be maintained. Shyam Bhartia Chairman said once the company brings new capital investments with value-added products, it expects margins to be improving.
Q&A Insights: Dhaval Shah of Svan Investments asked about the INR9,000 crore rev. target, if it’s achievable by FY27. Prakash Bisht CFO said that it can be achieved as the investments JUBLINGREA is making will be ready by FY25 and it only takes 2 years to ramp up the facilities.
Q&A Insights: Bajrang Bafna with Sunidhi Securities asked if the company is thinking on securing long term supply of ethanol. Shyam Bhartia Chairman clarified that it makes business sense for it to sell better quality of ethanol it makes at higher margins and consume from import.
To read further on the detailed analysis of #JUBLINGREA#Q4 concall Q&A …
LALPATHLAB said it saw significant shift towards direct-to-home business, with home collections now contributing nearly 12%, which used to be in the range of 5-6% during pre-COVID days. Also the company saw bundled packages continuing to rise.
Q&A Insights: Prakash Kapadia of Anived asked why the growth was lower in organic non-COVID revenue that was only up 4% in 4Q YonY. Arvind Lal EC said that in month of Jan. non-COVID was fairly low, mainly due to Omicron wave, however, the company exited on a good note in 4Q.
NEOGEN said FY22 has been the best year in its history with highest level of growth in revenues at 69% in 4Q22 and 45% in FY22.
Q&A Insights: Anshul Verdia from @EdelweissFin asked that on the organic chemicals revenue, what led to the moderation QonQ of INR6 crore in terms of topline. Harin Kanani MD said it was driven by product mix and mainly because NEOGEN was trying to develop some new molecules.
Q&A Insights: Ashutosh Tiwari of @EquirusGroup asked if Waluj machinery is still usable or if the capex be incurred later on. Rajiv Poddar Joint MD replied that at the moment it is usable and since there is a strong demand, the company is continuing to use it.
Q&A Insights: Ashutosh Tiwari of @EquirusGroup also asked about the capex number for FY23. Rajiv Poddar Joint MD answered that it will be roughly INR900 crores for FY23.
Q&A Insights: Rahul Jain of @Dolat_Capital asked about the potential for growth going forward. Anuj Khanna MD replied that historically AFFLE has been beating the overall industry growth trend. Therefore, AFFLE believes it will continue to deliver superior growth vs. industry avg
Q&A Insights: Rahul of @Dolat_Capital enquired about how capex tech capitalization in FCF has played out and outlook. Kapil CFO said AFFLE’s investment in innovations was about INR6.9-7 million for FY22. Plan for FY23 is about 4% +/- 25 bp to invest in innovations of top line.
POONAWALLA said its Housing arm delivered its highest ever profit before tax of INR101 crores against INR14 crores last year.
Q&A Insights: Nikhil Rungta of @NipponIndiaMF asked about the 30 BP impact due to ESOPs on the opex side and its outlook. Sanjay CFO said that the charge may increase for FY23. But this is a notional charge to P&L and will get reflected multifold into performance of the company.
Q&A Insights: Tejas Shah of Spark Capital asked about realization split increase that happened between price increase and premiumization during FY22 and 4Q. Ramesh Dua MD replied that price increase was about 25% across all categories, in few categories more and few others less.
Q&A Insights: Tejas Shah with Spark Capital asked about Sparx brand in ecommerce platforms. Gaurav Dua EVP Marketing said that Sparx brand has done very well in e-commerce platform; the growth rate was more than 40%. So there is traction of sports shoe selling more on e-comm.